Allergy Therapeutics plc (AIM:AGY)
London · Delayed Price · Currency is GBP · Price in GBX 11.00
-0.30 (-2.65%)
At close: Dec 31, 2025
Allergy Therapeutics Income Statement
Financials in millions GBP. Fiscal year is July - June.
Millions GBP. Fiscal year is Jul - Jun.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2016 - 2020 |
| 55.04 | 55.2 | 59.59 | 72.77 | 84.33 | Upgrade | |
Revenue Growth (YoY) | -0.28% | -7.36% | -18.11% | -13.71% | 7.83% | Upgrade |
Cost of Revenue | 25.74 | 25.46 | 26.34 | 23.26 | 22.11 | Upgrade |
Gross Profit | 29.3 | 29.74 | 33.25 | 49.51 | 62.23 | Upgrade |
Selling, General & Admin | 38.61 | 37.62 | 49.17 | 46.96 | 45.98 | Upgrade |
Research & Development | 15.38 | 22.9 | 20.12 | 15.66 | 12.89 | Upgrade |
Amortization of Goodwill & Intangibles | 0.56 | 0.53 | - | - | - | Upgrade |
Other Operating Expenses | -1.24 | -1.53 | -0.86 | -0.74 | -0.57 | Upgrade |
Operating Expenses | 57.79 | 64.07 | 68.43 | 61.88 | 58.3 | Upgrade |
Operating Income | -28.49 | -34.34 | -35.19 | -12.37 | 3.93 | Upgrade |
Interest Expense | -6.37 | -3.79 | -2.16 | -0.54 | -0.39 | Upgrade |
Interest & Investment Income | 0.38 | 0.29 | 0.33 | 0.25 | 0.11 | Upgrade |
Other Non Operating Income (Expenses) | -5.16 | -0.09 | - | 0 | 0.01 | Upgrade |
EBT Excluding Unusual Items | -39.63 | -37.93 | -37.02 | -12.66 | 3.66 | Upgrade |
Merger & Restructuring Charges | - | -1.24 | - | - | - | Upgrade |
Other Unusual Items | 0.43 | - | -4.75 | - | - | Upgrade |
Pretax Income | -39.2 | -39.17 | -41.77 | -12.66 | 3.66 | Upgrade |
Income Tax Expense | 0.93 | -0.55 | 1.31 | 1.12 | 0.77 | Upgrade |
Net Income | -40.13 | -38.62 | -43.07 | -13.78 | 2.89 | Upgrade |
Net Income to Common | -40.13 | -38.62 | -43.07 | -13.78 | 2.89 | Upgrade |
Net Income Growth | - | - | - | - | -59.11% | Upgrade |
Shares Outstanding (Basic) | 4,766 | 3,743 | 670 | 643 | 639 | Upgrade |
Shares Outstanding (Diluted) | 4,766 | 3,743 | 670 | 643 | 677 | Upgrade |
Shares Change (YoY) | 27.33% | 458.41% | 4.26% | -4.98% | 0.47% | Upgrade |
EPS (Basic) | -0.01 | -0.01 | -0.06 | -0.02 | 0.00 | Upgrade |
EPS (Diluted) | -0.01 | -0.01 | -0.06 | -0.02 | 0.00 | Upgrade |
EPS Growth | - | - | - | - | -59.06% | Upgrade |
Free Cash Flow | -31.37 | -35.54 | -33.55 | -17.06 | 6.03 | Upgrade |
Free Cash Flow Per Share | -0.01 | -0.01 | -0.05 | -0.03 | 0.01 | Upgrade |
Gross Margin | 53.23% | 53.87% | 55.79% | 68.03% | 73.79% | Upgrade |
Operating Margin | -51.75% | -62.20% | -59.05% | -17.00% | 4.66% | Upgrade |
Profit Margin | -72.91% | -69.97% | -72.28% | -18.93% | 3.42% | Upgrade |
Free Cash Flow Margin | -57.00% | -64.38% | -56.30% | -23.44% | 7.15% | Upgrade |
EBITDA | -26.18 | -32.17 | -33.08 | -10.24 | 6.11 | Upgrade |
EBITDA Margin | -47.56% | -58.27% | -55.51% | -14.07% | 7.25% | Upgrade |
D&A For EBITDA | 2.31 | 2.17 | 2.11 | 2.13 | 2.19 | Upgrade |
EBIT | -28.49 | -34.34 | -35.19 | -12.37 | 3.93 | Upgrade |
EBIT Margin | -51.75% | -62.20% | -59.05% | -17.00% | 4.66% | Upgrade |
Effective Tax Rate | - | - | - | - | 21.08% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.